Xeris Biopharma Holdings, Inc. revises revenue guidance for the full year 2023. For the year, the company tightening revenue guidance from $155 million - $165 million to $160 million - $165 million, which is at the high end of company's original range.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.005 USD | +5.53% | +9.19% | -14.04% |
09/05 | Transcript : Xeris Biopharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
09/05 | Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.04% | 28Cr | |
+31.49% | 59TCr | |
-3.39% | 36TCr | |
+19.26% | 33TCr | |
+5.20% | 29TCr | |
+15.36% | 24TCr | |
+9.99% | 21TCr | |
-6.91% | 20TCr | |
+9.97% | 17TCr | |
-0.50% | 16TCr |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings, Inc. Revises Revenue Guidance for the Full Year 2023